Результаты поиска

Proteomics-Based Approach for Detailing the Allergenic Profile of Cannabis Chemotypes.

Allergic sensitization to cannabis is an emerging public health concern and is difficult to clinically establish owing to lack of standardiz … ens of cannabis. Cannabis extracts were generated from high tetrahydrocannabinol variety (Mx), high cannabidiol variety (V1-19) and mixed profile variety (B5) using a Plant Total Protein Extraction Kit. Hemp extracts were generated using other standardized methods. Protein samples were subjected to nanoscale tandem mass spectrometry. Acquired peptides sequenc …

Herbal supplement use among reproductive-aged women in an academic infertility practice.

OBJECTIVE: To address the knowledge gap surrounding herbal medicine and supplement usage patterns and supplement-prescription medication int … osed mechanisms of interaction were CYP3A4 and CYP2C19 inhibition. In terms of safety in pregnancy, cannabidiol and chasteberry were suggested to be "possibly unsafe in pregnancy," and red raspberry leaf "likely unsafe in pregnancy" without direct medical supervision. CONCLUSIONS: We found over two thirds of women seeking treatment for infertility reported p …

Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series.

BACKGROUND: The use of cannabis for treating fibromyalgia syndrome (FMS) has not been comprehensively investigated. Thus, we have assessed the efficacy and adverse events (AEs) of short- and long-term medical cannabis (MC) treatment for FMS. METHODS: Data were obtained from medical reports archived in the pain clinic of Ponderano (Italy; retrospective study). FMS patients, who were resistant to conventional therapy, received licensed MC with various Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) content, as powdered whole flowers (decoction or vaporization) or oil extracts. Demographic …

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

IMPORTANCE: There are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), dev … A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial interventions during a 9-day admission. MAIN OUTCOMES AND MEASURES: Severity of cannabis withdrawal and cravings (Cannabis Withdrawal Scale), retention in withdrawal treatment, and adverse events. Secondar …

Cannabinoids and sleep bruxism: mechanistic rationale, polysomnographic evidence, and future research directions.

PURPOSE: Sleep bruxism (SB) is masticatory muscle activity during sleep, most often studied through its polysomnographic marker, rhythmic masticatory muscle activity (RMMA). Cannabinoids have attracted interest for their analgesic, anxiolytic and sleep-modulating properties, but whether they influence SB, and whether such modulation would benefit patients, remains unclear. This review examines cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabinol (CBN) in relation to sleep, arousal and masticatory muscle activity, and separates what has been demonstrated from what is inferred. METHODS:…

CBD-Containing Topical Formulation for Localized Pain in Fibromyalgia: A 12-Week Pilot Feasibility Study.

BACKGROUND: Fibromyalgia (FM) is a chronic pain condition characterized by widespread pain, fatigue, and functional impairment. Current pharmacological treatments show limited efficacy and poor tolerability. Cannabidiol (CBD) has demonstrated analgesic and anti-inflammatory properties, but evidence regarding CBD-containing topical formulations in FM remains scarce. OBJECTIVES: To evaluate the feasibility, safety, and preliminary efficacy of a CBD-containing topical formulation for localized pain in patients with FM and to explore its potential impact on broader symptom domains. MATERIAL AND …

Epileptic and developmental encephalopathy secondary to inversion-duplication of chromosome 15: Description of epilepsy characteristics and therapeutic outcomes.

OBJECTIVE: Inversion-duplication syndrome of chromosome 15 (invdup15) is a chromosomal disorder characterized by an inverted duplication of … racetam showed limited efficacy. In LGS, oxcarbazepine (8/12, 66%), valproic acid (11/18, 61%), and cannabidiol (6/9, 66%) yielded the best responses. All patients had early developmental delay; autism spectrum disorder was diagnosed in 22 of 54 (41%) and behavioral disorders in 30 of 54 (56%). SIGNIFICANCE: Epilepsy in invdup15 is highly drug-resistant and …

Позиции клиников и знания о медицинском каннабисе в клиниках по лечению опиоидной зависимости в Новом Южном Уэльсе, Австралия.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Предварительных исследований, касающихся отношения к опиоидной лечебной программе (ОТП) и знаний о прописываемом медицинском каннабисе у клиентов ОТП, не проводилось. В этом исследовании были проанализированы опыт медицинского лечения каннабиса, знания, проблемы и потребности в области образования. МЕТОДЫ: Сотрудники шести государственных служб прокуратуры в Новом Южном Уэльсе завершили обследование в области медицины каннабиса. В состав персонала входили медсестры, врачи, фармацевты, работники здравоохранения и потребительские работники. Для оценки влияния на пол, роль

Совпадение в аннотации оригинала
BACKGROUND: There are no prior studies investigating the attitudes and knowledge of opioid treatment program (OTP) clinicians on prescribed … ree conditions most identified as having sufficient evidence to support the routine clinical use of cannabidiol (CBD)-based medicinal cannabis were chronic pain (64.9%, 63/97), palliative care (62.5%, 60/96), and sleep problems (44.8%, 43/96). The most common educational needs identified by participants were the evidence for the effectiveness of medicinal can …

Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database.

BACKGROUND AND OBJECTIVE: CDKL5 deficiency disorder presents as a challenging condition with early-onset refractory seizures, severe develop … opiramate, sodium valproate, vigabatrin, phenobarbital and clobazam as the most used ASMs. Notably, cannabidiol showed highly beneficial outcomes with few side effects, whereas levetiracetam and phenobarbital exhibited less favourable benefit-to-side-effect ratios. Dual therapy involving sodium valproate and levetiracetam was only used a small number (n = 5) …

A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance.

BACKGROUND AND OBJECTIVES: Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of … d by sleep disorder (n = 18) and anxiety (n = 11). The mean (SD) delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) dose administered by participants was 9.61 (8.52) mg/9.15 (10.11) mg among those using an oil, and 37.00 (24.53) mg/0.38 (1.58) mg among those who vaporized flower, respectively. Participants' performance improved over time on the CANTAB Multi …

Top 20 Research Studies of 2022 for Primary Care Physicians.

This article summarizes the top 20 research studies of 2022 identified as POEMs (patient-oriented evidence that matters), excluding COVID-19 … he duration of an initial varenicline prescription should be 12 weeks. Many drugs can interact with cannabidiol. No important difference was found among ibuprofen, ketorolac, and diclofenac for treatment of acute nonradicular low back pain in adults.

Increased White Matter Coherence Following Three and Six Months of Medical Cannabis Treatment.

Background: Previous studies have demonstrated abnormal white matter (WM) microstructure in recreational cannabis consumers; however, the lo … d to confounding factors. Interestingly, significant reductions in MD values correlated with higher cannabidiol (CBD) exposure but not Δ-9-tetrahydrocannabinol exposure. Conclusions: Overall, MC treatment was associated with increased WM coherence, which contrasts with prior research examining recreational cannabis consumers, likely related to inherent differ …

A Case of Vaping TCH Oil Leading to Vaping Associated Pulmonary Injury: Our Approach to Its Diagnosis, Management, and Recommendations.

Vaping's popularity has grown exponentially since its introduction to the US market in 2003. Its use has sky-rocketed since the unveiling of the vaping pods in 2017 which may account for the advent of the vaping related illnesses we are now seeing. Substances such as nicotine solution, tetrahydrocannabinol (THC) oil, cannabidiol (CBD) oil, and butane hash oil (BHC) packaged in cartridges available in various flavors and concentrations are aerosolized by the heating of metal coils in the e-cigarette/vaping devices. Cases from all over the country have recently been coming to light in which vapi…

In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function.

Introduction: Legalization of medicinal cannabis around the world has led to an increase in the use of commercial cannabis-based products in … oducts (Spectrum Yellow™, Tweed Argyle, and Spectrum Red™) that contain differing concentrations of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) were evaluated for DDI potential at 12 drug transporters. HEK293 cells or vesicles expressing human ABC transporters (ABCB1, ABCC2, ABCG2, or ABCB11) and SLC transporters (SLC22A1, SLC22A2, SLC22A6, SLC22A8 …

Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019.

IMPORTANCE: Since August 2019, more than 2700 patients have been hospitalized with e-cigarette, or vaping, product use-associated lung injur … ents interviewed, 71 (83%) reported vaping tetrahydrocannabinol (THC)-containing products, 36 (43%) cannabidiol (CBD)-containing products, and 39 (47%) nicotine-containing products. Sixty-five of 87 (75%) THC-containing products were reported as obtained from informal sources, such as friends, acquaintances, or unlicensed retailers. Of 87 vaping products test …

Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.

AIMS/HYPOTHESIS: Abnormal cannabidiol (Abn-CBD) and AS-1269574 are potent selective agonists for GPR55 and GPR119, respectively. The present study evaluated the actions and ability of these small-molecule agonists to counteract experimental diabetes in mice. METHODS: Diabetes was induced in NIH Swiss mice by five consecutive daily intraperitoneal injections of 40 mg/(kg body weight) streptozotocin. Diabetic mice received daily oral administration of Abn-CBD or AS-1269574 (0.1 μmol/kg) or saline vehicle (0.9% wt/vol. NaCl) over 28 days. Body weight, food intake, fluid intake, plasma glucose, i…

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

BACKGROUND: Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients. OBJECTIVE: To compare Sativex with placebo in relieving symptoms of spasticity due to MS. METHODS: A 15-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study in 337 subjects with MS spasticity not fully relieved with current anti-spasticity therapy. RESULTS: The primary endpoint was a spasticity 0-10 numeric rating scale (NRS). Intention-to-treat (ITT) analysis showed a non-significant improvement in NRS score, in favor of Sativex. The per protocol (PP)

Semi-synthetic cannabinoids: Recent developments, analytical challenges and strategic responses.

The emergence and proliferation of semi-synthetic cannabinoids (SSCs) represents a significant evolution in the European new psychoactive substances (NPS) landscape. SSCs, are substances that mimic the effects of delta-9 tetrahydrocannabinol (THC or delta-9-THC), the substance primarily responsible for the major psychoactive effects of cannabis. They are marketed as 'legal' replacements to cannabis and delta-9 THC and can be produced from cannabidiol (CBD) extracted from low-THC cannabis (hemp). Since the first detection of hexahydrocannabinol (HHC) in Europe in late 2022, the SSC market has r…

Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.

INTRODUCTION: Gilles de la Tourette syndrome (GTS) is a childhood onset disorder characterised by the presence of motor and vocal tics. The … biximols' [Title/Abstract] OR 'tetrahydrocannabinol' [Title/Abstract] OR 'THC' [Title/Abstract] OR 'cannabidiol' [Title/Abstract], limit: 'humans'. These studies were further reviewed for additional relevant citations. The titles and abstracts of the studies obtained through this search were examined by two reviewers (KS, NS) in order to determine article inc …

Cannabinoids in clinical practice.

Cannabis has a potential for clinical use often obscured by unreliable and purely anecdotal reports. The most important natural cannabinoid is the psychoactive tetrahydrocannabinol (delta9-THC); others include cannabidiol (CBD) and cannabigerol (CBG). Not all the observed effects can be ascribed to THC, and the other constituents may also modulate its action; for example CBD reduces anxiety induced by THC. A standardised extract of the herb may be therefore be more beneficial in practice and clinical trial protocols have been drawn up to assess this. The mechanism of action is still not fully …